2017
DOI: 10.5694/mja17.00514
|View full text |Cite
|
Sign up to set email alerts
|

Trends in meningococcal disease: challenges for vaccine control when disease is rare

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2018
2018
2018
2018

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 16 publications
0
1
0
1
Order By: Relevance
“…The reason proposed by the 56.6% of physicians who think that the vaccine does not need to enter the national vaccine scheme has been the higher cost of vaccination. It has also been shown in studies in various countries that the decisions taken in the national vaccine scheme for diseases that are less frequent face with difficulties, and the cost concerns are the most effective difficult in this matter (14,19,20,(22)(23)(24)(25)(26)(27). Also, the priority of entering national schemes in these studies conducted in our country and in the world is firstly the financial concerns and the second concern is the frequency of the illness (14,19).…”
Section: Discussionmentioning
confidence: 97%
“…The reason proposed by the 56.6% of physicians who think that the vaccine does not need to enter the national vaccine scheme has been the higher cost of vaccination. It has also been shown in studies in various countries that the decisions taken in the national vaccine scheme for diseases that are less frequent face with difficulties, and the cost concerns are the most effective difficult in this matter (14,19,20,(22)(23)(24)(25)(26)(27). Also, the priority of entering national schemes in these studies conducted in our country and in the world is firstly the financial concerns and the second concern is the frequency of the illness (14,19).…”
Section: Discussionmentioning
confidence: 97%
“…Aşının ulusal aşı şemasına girmesi gerekmediğini düşünen hekimlerin %56.6 oranıyla en önde bildirdikleri sebep aşının maliyetinin yüksek olmasıydı. Çeşitli ülkelerde yapılan çalışmalarda da gösterilmiştir ki özellikle daha az sıklıkta görülen hastalıklar için ulusal aşı şemasına alınma kararları zorluklar içermektedir, bu zorlukların başında maliyet kaygıları ön plandadır (14,19,20,(22)(23)(24)(25)(26)(27). Yine ülkemizde ve dünyadaki bu çalışmalarda ulusal şemalara girme önceliğinin hastalık sıklığı açısısından aşı için daha geri planda olması mali kaygılardan sonra ikinci sırayı almıştır (14,19).…”
Section: Introductionunclassified